Professor Shirley X.Y. Wu of the Leslie Dan Faculty of Pharmacy at the University of Toronto has been named a Fellow of the American Association of Pharmaceutical Scientists (AAPS) which was induced at the AAPS Annual Meeting in San Diego this month. Professor Wu’s election as a Fellow signals the international recognition of her distinguished and sustained accomplishments and contributions to the advancement of pharmaceutical sciences, particularly in the field of Controlled Drug Delivery and Modified Release Formulations.
Over her 20-year academic career, Professor Wu has become an internationally recognized expert and leader in novel nanoparticle drug delivery strategies for enhancing chemotherapy of multidrug resistant (MDR) and metastatic cancers, computational analysis and design of modified release dosage forms towards Quality-by-Design, and nanotechnology-based intelligent drug delivery systems.
During this time, she has created a novel polymer-lipid hybrid nanoparticle system which increases efficacy, reduces systemic toxicity, and enables simultaneous delivery of synergistic drug combinations to overcome MDR in cancer. Professor Wu has designed a state-of-art glucose-responsive insulin delivery device by elegant combination of materials science, nanotechnology, and mathematical modeling, which can provide closed-loop delivery of therapeutics on demand. She is a co-author of over 300 scientific publications and co-inventor of 18 issued and pending patents worldwide. The high quality of Professor Wu’s research is reflected in her citation index and the impact factors of the journals where she has published her work. Her dedication to graduate and undergraduate education is reflected by her development of several new courses and role in teaching a number of pharmaceutics and drug delivery courses. Moreover, she has mentored over 120 postdoctoral fellows, graduate, and undergraduate research students. Professor Wu’s recent research continues to be at the forefront of controlled drug delivery and pharmaceutical nanotechnology, which includes the creation of multifunctional polymer nanotheranostics for brain cancer and diseases in the central nervous system (CNS), as well as bioreactive metal oxide nanoparticles for modulating tumor microenvironment and enhancing cancer therapies.
“I am humbled to have my accomplishments and contributions acknowledged by the AAPS through my election as a Fellow of the premier scientific organization in our field,” noted Professor Wu. “Being recognized by international experts and peers in the field is a huge reward to me and my research group.”
“I have been fortunate to work with passionate collaborators and highly talented, self-motivated, and hard-working graduate students and postdoctoral researchers throughout my career. As a result, I share this honor with them and look forward to working with my current team to make new breakthroughs and develop more effective and safer therapeutic approaches for the treatment of diseases that affect millions of people.”
The American Association of Pharmaceutical Scientists is a professional, scientific association of approximately 11,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to serve the public and enhance their contributions to health. AAPS offers timely scientific programs, on-going education, information resources, opportunities for networking, and professional development. For more information, please visit www.aaps.org.